{"prompt": "['investigator on the Adverse Event eCRF. The PRO data will be presented in separate tables,', 'figures, and data listings from the adverse event data, and will be included in the appropriate', 'section of the final study report.', '5.4', 'IMMEDIATE REPORTING REQUIREMENTS FROM INVESTIGATOR', 'TO SPONSOR', 'Certain events require immediate reporting to allow the Sponsor to take appropriate', 'measures to address potential new risks in a clinical trial. The investigator must report such', 'events to the Sponsor immediately; under no circumstances should reporting take place', 'more than 24 hours after the investigator learns of the event. The following is a list of events', 'that the investigator must report to the Sponsor within 24 hours after learning of the event,', 'regardless of relationship to emicizumab:', 'Serious adverse events (see Section 5.4.2 for further details)', 'Adverse events of special interest (see Section 5.4.2 for further details)', 'Pregnancies (see Section 5.4.3 for further details).', 'The investigator must report new significant follow-up information for these events to the', 'Sponsor immediately (i.e., no more than 24 hours after becoming aware of the information).', 'New significant information includes the following:', 'New signs or symptoms or a change in the diagnosis', 'Significant new diagnostic test results', 'Change in causality based on new information', \"Change in the event's outcome, including recovery\", 'Additional narrative information on the clinical course of the event.', 'Investigators must also comply with local requirements for reporting serious adverse events', 'to the local health authority and Institutional Review Board/Ethics Committee (IRB/EC).', '5.4.1', 'Emergency Medical Contacts', 'To ensure the safety of study patients, an Emergency Medical Call Center Help Desk will', 'access the Roche Medical Emergency List, escalate emergency medical calls, provide', 'medical translation service (if necessary), connect the investigator with a Roche Medical', 'Responsible individual, and track all calls. The Emergency Medical Call Center Help Desk', 'will be available 24 hours per day, 7 days per week. Toll-free numbers for the Help Desk, as', 'well as Medical Monitor and Medical Responsible individual contact information, will be', 'distributed to all investigators.', '5.4.2', 'Reporting Requirements for Serious Adverse Events and Adverse', 'Events of Special Interest', '5.4.2.1', 'Events That Occur prior to Study Drug Initiation', 'After informed consent has been obtained but prior to initiation of emicizumab, only serious', 'adverse events caused by a protocol-mandated intervention should be reported. The', 'Serious Adverse Event/Adverse Event of Special Interest Reporting Form provided to', 'investigators should be completed and submitted to the Sponsor or its designee immediately', 'Emicizumab - F. Hoffmann-La Roche Ltd', '139 / Protocol MO39129, Version 3']['(i.e., no more than 24 hours after learning of the event), either by faxing or by scanning and', 'emailing the form using the fax number or email address provided to investigators.', '5.4.2.2', 'Events That Occur after Study Drug Initiation', 'After initiation of emicizumab, serious adverse events and adverse events of special interest', 'will be reported until the last scheduled study visit (see Section 5.3.1). Investigators should', 'record all case details that can be gathered immediately (i.e., within 24 hours after learning', 'of the event) on the Adverse Event eCRF and submit the report via the electronic data', 'capture (EDC) system. A report will be generated and sent to Roche Safety Risk', 'Management by the EDC system.', 'In the event that the EDC system is unavailable, the Serious Adverse Event/Adverse Event', 'of Special Interest Reporting Form provided to investigators should be completed and', 'submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours after', 'learning of the event), either by faxing or by scanning and emailing the form using the fax', 'number or email address provided to investigators. Once the EDC system is available, all', 'information will need to be entered and submitted via the EDC system.', 'Instructions for reporting serious adverse events that occur after the patient has completed', 'the 2-year treatment period are provided in Section 5.6.', '5.4.3', 'Reporting Requirements for Pregnancies', '5.4.3.1', 'Pregnancies in Female Patients', 'Female patients of childbearing potential will be instructed to immediately inform the', 'investigator if they become pregnant during the study or within 24 weeks after the last dose', 'of emicizumab. A Clinical Trial Pregnancy Reporting Form should be completed and', 'submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours after', 'learning of the pregnancy), either by faxing or by scanning and emailing the form using the', 'fax number or email address provided to investigators. Pregnancy should not be recorded on', 'the Adverse Event eCRF. The investigator should discontinue emicizumab and counsel the', 'patient, discussing the risks of the pregnancy and the possible effects on the fetus.', 'Monitoring of the patient should continue until conclusion of the pregnancy. Any serious', 'adverse events associated with the pregnancy (e.g., an event in the fetus, an event in the', 'mother during or after the pregnancy, or a congenital anomaly/birth defect in the child)', 'should be reported on the Adverse Event eCRF. In addition, the investigator will submit a', 'Clinical Trial Pregnancy Reporting Form when updated information on the course and', 'outcome of the pregnancy becomes available.', '5.4.3.2', 'Pregnancies in Female Partners of Male Patients', 'Although embryo-fetal development studies are not available, condom use will not be', 'required in male patients enrolled in the study, as the margin between the minimal', 'anticipated biological effect level (MABEL) plasma concentration (7 ng/mL) and the', 'estimated maternal Cmax (for both the 1.5 and 3.0 mg/kg per week dosing regimens) is', 'greater than 10-fold (Banholzer et al. 2012). At this time, very little emicizumab is thought to', 'transfer into semen, and there are no known reproductive risks to female partners of male', 'patients treated with emicizumab. Therefore, contraception use by male patients is not', 'Emicizumab - F. Hoffmann-La Roche Ltd', '140 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}